-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the top academic journal "Nature" published an important paper on the new crown infection online in the form of "Accelerated Article Preview", which brings us good news.
The research team of Washington University School of Medicine in St.
“There was a report last fall that the antibodies produced after infection with the new crown virus will decay rapidly.
Dr.
The researchers pointed out that to figure out whether COVID-19 will cause durable antibody protection, the key lies in the bone marrow.
So, do mild patients infected with the new coronavirus have such long-lived plasma cells and continue to produce neutralizing antibodies specifically against the new coronavirus? In order to confirm this, the research team recruited 77 patients with mild illness for an 11-month follow-up analysis.
These infected people will undergo blood tests every three months starting approximately one month after the first symptoms appear.
At the same time, the researchers performed bone marrow aspiration on 18 of the experimental participants in the 7th to 8th months after infection, and analyzed the cells in the bone marrow samples.
Five of the participants also provided a second bone marrow sample after a few months of separation, and the S protein-specific BMPC could still be found again, indicating that these cells are stable.
For comparison, the researchers also obtained bone marrow samples from 11 people who had never been infected with the new coronavirus, and did not find the same BMPC.
"Patients with mild new coronary disease can clear the virus from the body within two or three weeks after infection, so there will be no active immune response caused by the virus for 7 to 11 months after infection.
The press release of the research institute pointed out that people who have recovered from the new coronary disease can get durable antibody protection, which means that the possibility of recurring COVID-19 symptoms is unlikely.
The researchers believe that further studies are needed to determine whether infected persons who have experienced more severe symptoms can avoid re-infection.
Another important question that researchers are continuing to study is whether vaccination will also allow us to produce these long-lived immune cells that produce antibodies.
Reference
[1] Jackson S.
[2] Good news: Mild COVID-19 induces lasting antibody protection.